Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Me

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Me

Novocure (NVCR) shares jump after trial meets primary endpoint

March 27, 2024 9:58 AM EDT

Shares of Novocure (NASDAQ: NVCR) jumped Wednesday after the company reported before the open that its phase 3 METIS clinical trial met its primary endpoint.

The company's lung cancer demonstrated the slowing in the progression of cancer to the brain in... More